The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

Teva Pharmaceuticals is suing the Centers for Medicare & Medicaid Services (CMS) for its implementation of the drug price negotiation program under the Inflation Reduction Act (IRA). | A new lawsuit from a drug manufacturer,

U.S. division has sued CMS over the Medicare drug pricing negotiations policy included in the Inflation Reduction Act. In its lawsuit filed in D.C. federal court, the Israel-based drugmaker says that guidance CMS has issued on price negotiations "gives the agency even more unchecked price-setting power